FDG-PET/CT for systemic staging of patients with newly diagnosed breast cancer

Groheux, David

doi:10.1007/s00259-017-3731-3

Cited by 15 publications

(16 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…An attempt to replicate molecular classification using conventional IHC characteristics of the tumor, including ER, PR, HER-2, and Ki67 showed low concordance with gene expressions profile (4,5). When it comes to breast cancer staging, 2-deoxy-2[18F]-fluoro-D-glucose ( 18 F-FDG) PET/CT is a well-established examination for the initial staging of locally advanced breast cancer (6)(7)(8)(9), as it displays excellent capabilities for extra-axillary nodal and distance metastases detection. On the contrary, for the local evaluation of primary breast lesion, 18 F-FDG PET/CT has so far been outperformed by echography and MRI mainly because of its lack of sensitivity (10,11).…”

Section: Introductionmentioning

confidence: 99%

Hormonal Receptor Immunochemistry Heterogeneity and 18F-FDG Metabolic Heterogeneity: Preliminary Results of Their Relationship and Prognostic Value in Luminal Non-Metastatic Breast Cancers

et al. 2021

View full text Add to dashboard Cite

IntroductionWe aimed to investigate whether 18F-FDG PET metabolic heterogeneity reflects the heterogeneity of estrogen receptor (ER) and progesterone receptor (PR) expressions within luminal non-metastatic breast tumors and if it could help in identifying patients with worst event-free survival (EFS).Materials and methodsOn 38 PET high-resolution breast bed positions, a single physician drew volumes of interest encompassing the breast tumors to extract SUVmax, histogram parameters and textural features. High-resolution immunochemistry (IHC) scans were analyzed to extract Haralick parameters and descriptors of the distribution shape. Correlation between IHC and PET parameters were explored using Spearman tests. Variables of interest to predict the EFS status at 8 years (EFS-8y) were sought by means of a random forest classification. EFS-8y analyses were then performed using univariable Kaplan-Meier analyses and Cox regression analysis. When appropriate, Mann-Whitney tests and Spearman correlations were used to explore the relationship between clinical data and tumoral PET heterogeneity variables.ResultsFor ER expression, correlations were mainly observed with 18F-FDG histogram parameters, whereas for PR expression correlations were mainly observed with gray-level co-occurrence matrix (GLCM) parameters. The strongest correlations were observed between skewness_ER and uniformity_HISTO (ρ = −0.386, p = 0.017) and correlation_PR and entropy_GLCM (ρ = 0.540, p = 0.001), respectively. The median follow-up was 6.5 years and the 8y-EFS was 71.0%. Random forest classification found age, clinical stage, SUVmax, skewness_ER, kurtosis_ER, entropy_HISTO, and uniformity_HISTO to be variables of importance to predict the 8y-EFS. Univariable Kaplan-Meier survival analyses showed that skewness_ER was a predictor of 8y-EFS (66.7 ± 27.2 versus 19.1 ± 15.2, p = 0.018 with a cut-off value set to 0.163) whereas other IHC and PET parameters were not. On multivariable analysis including age, clinical stage and skewness_ER, none of the parameters were independent predictors. Indeed, skewness_ER was significantly higher in youngest patients (ρ = −0.351, p = 0.031) and in clinical stage III tumors (p = 0.023).ConclusionA heterogeneous distribution of ER within the tumor in IHC appeared as an EFS-8y prognosticator in luminal non-metastatic breast cancers. Interestingly, it appeared to be correlated with PET histogram parameters which could therefore become potential non-invasive prognosticator tools, provided these results are confirmed by further larger and prospective studies.

show abstract

Section: Introductionmentioning

confidence: 99%

Hormonal Receptor Immunochemistry Heterogeneity and 18F-FDG Metabolic Heterogeneity: Preliminary Results of Their Relationship and Prognostic Value in Luminal Non-Metastatic Breast Cancers

et al. 2021

View full text Add to dashboard Cite

show abstract

“…[4,5] In recent years, 18F-fluoro-deoxy-glucose-positron emission tomography / computed tomography (FDG-PET/CT) is more accurate than conventional imaging for the examination of high-risk primary breast cancer in stage IIB or higher regardless of age, malignancy grade, and receptor status. [6][7][8] Compared to conventional imaging, more metastases are detected by FDG-PET/CT to the internal mammary lymph nodes, infra-or supraclavicular nodes, and distant sites. [5,6,8,9] Stage migration from an initial less advanced stage into a more advanced stage of the disease could have the potential to improve stage-specific survival in early-stage breast cancer due to a more correct allocation into stages.…”

Section: Introductionmentioning

confidence: 99%

FDG-PET/CT in high-risk primary breast cancer—a prospective study of stage migration and clinical impact

Vogsen

Jensen

Christensen

et al. 2020

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…[ 17 ] Several studies showed that 18 F FDG PET/CT scan was the most sensitive test to detect extra-axillary lymph node metastases and distant organ metastases. [ 5 12 13 14 18 ] The NCCN guidelines recommend 18 F FDG PET/CT scan in breast cancer for Stage IIIA and above.…”

Section: Discussionmentioning

confidence: 99%

“…[ 11 ] Recently, some studies showed the role of 18 F FDG PET/CT scan in breast cancer with Stage II. [ 12 13 14 ]…”

Section: Introductionmentioning

confidence: 99%

Role of ¹⁸F-Fluorodeoxyglucose positron-emission tomography/computed tomography scan in primary staging of breast cancer compared to conventional staging

2018

View full text Add to dashboard Cite

FDG-PET/CT for systemic staging of patients with newly diagnosed breast cancer

Cited by 15 publications

References 21 publications

Hormonal Receptor Immunochemistry Heterogeneity and 18F-FDG Metabolic Heterogeneity: Preliminary Results of Their Relationship and Prognostic Value in Luminal Non-Metastatic Breast Cancers

Hormonal Receptor Immunochemistry Heterogeneity and 18F-FDG Metabolic Heterogeneity: Preliminary Results of Their Relationship and Prognostic Value in Luminal Non-Metastatic Breast Cancers

FDG-PET/CT in high-risk primary breast cancer—a prospective study of stage migration and clinical impact

Role of ¹⁸F-Fluorodeoxyglucose positron-emission tomography/computed tomography scan in primary staging of breast cancer compared to conventional staging

Contact Info

Product

Resources

About

FDG-PET/CT for systemic staging of patients with newly diagnosed breast cancer

Cited by 15 publications

References 21 publications

Hormonal Receptor Immunochemistry Heterogeneity and 18F-FDG Metabolic Heterogeneity: Preliminary Results of Their Relationship and Prognostic Value in Luminal Non-Metastatic Breast Cancers

Hormonal Receptor Immunochemistry Heterogeneity and 18F-FDG Metabolic Heterogeneity: Preliminary Results of Their Relationship and Prognostic Value in Luminal Non-Metastatic Breast Cancers

FDG-PET/CT in high-risk primary breast cancer—a prospective study of stage migration and clinical impact

Role of 18F-Fluorodeoxyglucose positron-emission tomography/computed tomography scan in primary staging of breast cancer compared to conventional staging

Contact Info

Product

Resources

About

Role of ¹⁸F-Fluorodeoxyglucose positron-emission tomography/computed tomography scan in primary staging of breast cancer compared to conventional staging